Frequently Asked Questions about Sanofi (SNY)

Name: Sanofi (SNY) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Sanofi (SNY) do?

Accepted Answer

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty ...

Question 2

Is Sanofi (SNY) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of SNY reveals an Altman Z-Score of 1.74 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($46.72B most recent), help investors decide if SNY fits their risk profile.

Question 3

What is the current P/E ratio for SNY?

Accepted Answer

As of the latest trading session, Sanofi (SNY) has a trailing P/E ratio of 9.29.

Question 4

Who is the CEO of Sanofi?

Accepted Answer

The current Chief Executive Officer of Sanofi is Olivier Charmeil.

Question 5

What was SNY's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Sanofi reported annual revenues of $46.72B (2025), $44.29B (2024), $41.62B (2023), $40.56B (2022), $39.17B (2021) respectively.

Question 6

Does SNY pay a dividend?

Accepted Answer

Sanofi currently pays a dividend to its shareholders, with a trailing dividend yield of 4.85%.

Question 7

How much debt and cash flow does SNY have?

Accepted Answer

In its latest reporting period, Sanofi generated $8.89B in Free Cash Flow against a total debt load of $21.79B.

Question 8

What is the Price-to-Book (P/B) ratio of Sanofi?

Accepted Answer

The Price-to-Book (P/B) ratio for Sanofi (SNY) is currently 1.38.

Question 9

What is the Price-to-Sales (P/S) ratio of SNY?

Accepted Answer

Based on trailing twelve-month data, Sanofi (SNY) trades at a Price-to-Sales (P/S) ratio of 1.67.

Question 10

What is Sanofi's Return on Equity (ROE)?

Accepted Answer

Sanofi (SNY) has a Return on Equity (ROE) of 14.71%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	10.8B	0	-1.9B	8.9B	8.9B
2024-12	9.1B	0	-3.2B	5.9B	5.9B
2023-12	10.3B	0	-1.6B	8.6B	8.6B
2022-12	10.5B	245M	-2.2B	8.3B	8.1B
2021-12	10.5B	244M	-2B	8.5B	8.2B

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	10.8B	0	-1.9B	8.9B	8.9B
2024-12	9.1B	0	-3.2B	5.9B	5.9B
2023-12	10.3B	0	-1.6B	8.6B	8.6B
2022-12	10.5B	245M	-2.2B	8.3B	8.1B
2021-12	10.5B	244M	-2B	8.5B	8.2B